Stockscreener 앱 받기
11.25
3.93%
-0.46
전일 마감가:
$11.71
열려 있는:
$11.75
하루 거래량:
1.30M
Relative Volume:
0.92
시가총액:
$1.46B
수익:
순이익/손실:
주가수익비율:
-18.48
EPS:
-0.6087
순현금흐름:
1주 성능:
-3.10%
1개월 성능:
-11.42%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.16
$11.79
1주일 범위
$10.44
$11.79
52주 변동 폭
$9.76
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
명칭
Kailera Therapeutics Inc
전화
508-440-9475
주소
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.25 | 1.46B | 0 | 0 | 0 | -0.6087 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-12 | 개시 | Evercore ISI | Outperform |
| 2026-05-12 | 개시 | JP Morgan | Overweight |
| 2026-05-12 | 개시 | Jefferies | Buy |
| 2026-05-12 | 개시 | Leerink Partners | Outperform |
| 2026-05-12 | 개시 | TD Cowen | Buy |
| 2026-05-12 | 개시 | William Blair | Outperform |
모두보기
Kailera Therapeutics Inc 주식(KLRA)의 최신 뉴스
Kailera Therapeutics (Nasdaq:KLRA)Stock Analysis - Simply Wall Street
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - stocktitan.net
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - TechStock²
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Archives - 24/7 Wall St.
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - Yahoo Finance
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
2 GLP-1 Stocks That Could Double Your Money by 2031 - The Motley Fool
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - stocktitan.net
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Australia
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Canada
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com India
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com UK
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings | KLRA Stock News - Quiver Quantitative
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - GlobeNewswire
Kailera Therapeutics Inc (KLRA) 재무 분석
Kailera Therapeutics Inc (KLRA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Kailera Therapeutics Inc 주식 (KLRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
3.77%
4.63%
자본화:
|
볼륨(24시간):